Marker Therapeutics, Inc. (MRKR) Financial Ratios
27 years of historical data (1999–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.00
—
5yr avg: 1.55
30Y Low0.0·High46.6
ROE
↑
-0.0%
↓+100% vs avg
5yr avg: -65.3%
30Y Low-470%·High-0%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MRKR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Marker Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $14M | $23M | $28M | $48M | $22M | $73M | $68M | $131M | $106M | $37M | $288M |
| Enterprise Value | $-16068033639010 | $-16068025188100 | $9M | $33M | $18M | $42M | $59M | $88M | $44M | $32M | $280M |
| P/E Ratio → | -1.68 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 4.24 | 14.63 | 6.32 | 58.55 | 146.12 | 615.87 | 514.33 | 202.43 | — |
| P/B Ratio | 0.00 | 0.00 | 1.50 | 3.45 | 1.13 | 1.65 | 2.49 | 2.98 | 1.79 | 10.13 | 46.56 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MRKR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 1.33 | 10.07 | 5.13 | 34.00 | 126.64 | 412.20 | 214.58 | 174.44 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
MRKR Profitability
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have expanded from -440.4% to -168.7% over the past 3 years, signaling improving operational efficiency. A negative ROE of -0.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | -104.3% | -214.6% | -240.6% | -154.7% | -3944.9% | -5887.4% | -60095.0% | -2768.4% | — |
| Operating Margin | — | — | -168.7% | -440.4% | -563.3% | -3179.3% | -6188.3% | -10567.3% | -71930.3% | -6271.0% | — |
| Net Profit Margin | — | — | -162.8% | -248.8% | -851.9% | -3372.7% | -6149.7% | -10050.9% | -71826.4% | -5999.0% | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -0.0% | -0.0% | -65.8% | -49.0% | -94.1% | -117.4% | -80.4% | -41.4% | -469.7% | -223.1% | -39.7% |
| ROA | -0.0% | -0.0% | -54.8% | -32.0% | -58.4% | -73.6% | -62.4% | -39.5% | -439.5% | -167.6% | -33.7% |
| ROIC | -0.0% | -0.0% | — | -152.1% | -102.6% | -186.5% | -229.1% | — | — | — | — |
| ROCE | -0.0% | -0.0% | -68.2% | -71.7% | -48.3% | -83.6% | -69.1% | -43.4% | -470.4% | -233.3% | -137.3% |
MRKR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $16.1T exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.39 | 0.27 | 0.45 | 0.01 | — | 0.00 | 0.00 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.96 | -1.03 | -1.08 | -0.21 | -0.69 | -0.33 | -0.98 | -1.04 | -1.40 | -1.27 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($16.07T) exceeds total debt ($0)
MRKR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Marker Therapeutics, Inc.'s current ratio of 8.39x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 5.57x to 8.39x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.39 | 8.39 | 6.36 | 5.57 | 2.14 | 3.56 | 3.81 | 22.83 | 22.11 | 3.40 | 4.56 |
| Quick Ratio | 8.39 | 8.39 | 6.36 | 5.89 | 2.14 | 3.56 | 3.81 | 22.83 | 22.11 | 3.40 | 4.56 |
| Cash Ratio | 7.07 | 7.07 | 5.54 | 4.91 | 1.51 | 3.28 | 3.34 | 22.03 | 22.02 | 3.37 | 4.52 |
| Asset Turnover | — | — | 0.30 | 0.19 | 0.10 | 0.02 | 0.01 | 0.00 | 0.00 | 0.04 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 129.96 | 113.30 | 249.53 | 0.07 | 782.38 | 96.20 | 191.68 | — | — |
MRKR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Marker Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.8% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.8% | 0.0% |
| Shares Outstanding | — | $15M | $9M | $9M | $8M | $8M | $5M | $5M | $2M | $945348 | $7M |
Peer Comparison
Compare MRKR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MRKRYou | $14M | -1.7 | — | — | — | — | -0.0% | -0.0% | — |
 FATE | $244M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 AGEN | $125M | -882.4 | — | — | 29.6% | -18.0% | — | — | — |
 ADCT | $139M | -1.0 | — | — | 90.6% | -133.2% | — | — | — |
 IMVT | $7B | -12.8 | — | — | — | — | -64.8% | — | — |
 CABA | $463M | -1.7 | — | — | — | — | -127.0% | -429.6% | — |
 KYMR | $7B | -24.5 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 ALKT | $2B | -31.9 | — | 38.0 | 57.8% | -12.1% | -13.3% | -8.6% | — |
 NKTR | $1B | -6.3 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 CRIS | $82M | -0.7 | — | — | 99.5% | -348.4% | -138.8% | — | — |
 TGTX | $8B | 19.2 | 67.4 | — | 83.7% | 20.0% | 102.8% | 16.4% | 2.1 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 27 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
MRKR — Frequently Asked Questions
Quick answers to the most common questions about buying MRKR stock.
What is Marker Therapeutics, Inc.'s P/E ratio?
Marker Therapeutics, Inc.'s current P/E ratio is -1.7x. This places it at the 50th percentile of its historical range.
What is Marker Therapeutics, Inc.'s ROE?
Marker Therapeutics, Inc.'s return on equity (ROE) is -0.0%. The historical average is -118.1%.
Is MRKR stock overvalued?
Based on historical data, Marker Therapeutics, Inc. is trading at a P/E of -1.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.